Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease

Background The tauopathy inhibitor, davunetide shows sex-dependent efficacy in women suffering from progressive supranuclear palsy. Extending these findings to prodromal Alzheimer’s disease, we submitted a double-blind, placebo-controlled, 12 weeks/16 weeks follow-up, davunetide clinical trial resul...

Full description

Saved in:
Bibliographic Details
Published in:Translational psychiatry 2024-10, Vol.14 (1), p.412-10, Article 412
Main Authors: Gozes, Illana, Blatt, Jason, Lobyntseva, Alexandra
Format: Article
Language:English
Subjects:
692/699
692/699/476
Aged
Alzheimer Disease - drug therapy
Alzheimer's disease
Autophagy
Behavioral Sciences
Biological Psychology
Brain research
Clinical trials
Cognition & reasoning
Cognitive ability
Cognitive Dysfunction - drug therapy
Cognitive Dysfunction - etiology
Cognitive Dysfunction - physiopathology
Dose-Response Relationship, Drug
Double-Blind Method
Drug dosages
Female
Females
Geriatrics
Humans
Hypotheses
Kinases
Male
Medicine
Medicine & Public Health
Memory
Memory, Short-Term - drug effects
Mental depression
Middle Aged
Neurodegeneration
Neurosciences
Pharmacotherapy
Prodromal Symptoms
Proteins
Psychiatry
Sex Factors
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The tauopathy inhibitor, davunetide shows sex-dependent efficacy in women suffering from progressive supranuclear palsy. Extending these findings to prodromal Alzheimer’s disease, we submitted a double-blind, placebo-controlled, 12 weeks/16 weeks follow-up, davunetide clinical trial results in amnestic mild cognitive impairment (ClinicalTrials.gov ID NCT00422981), to a sex-dependent analysis. Methods One hundred forty-four individuals, separated into eight groups (1:2 placebo—and 2 doses, 5 mg davunetide/daily or 15 mg davunetide/twice-daily, with matching placebo intranasal volumes), were evaluated. Results Significant dose-dependent cognitive increases were observed in men compared to women with a test of delayed (12 ss) visual matching to the sample. In a test of semantic working memory and attention (digit span), women showed a significant low-dose placebo effect, ensuing in a high dose significant davunetide improvement, over the matched placebo. Correlating anxiety with cognition showed sex-opposing results, with women depicting significant anxiety correlations with delayed matching to sample. Discussion In conclusion, sex-specific prodromal Alzheimer’s drug development is encouraged, with davunetide playing a lead initiative role.
ISSN:2158-3188
2158-3188
DOI:10.1038/s41398-024-03118-0